July 16, 2019 11:00 AM - 12:00 PM3-001 ECHA
Add event to Google Calendar
The School of Public Health is pleased to welcome Feng Xie, professor, Department of Health Research Methods, Evidence and Impact, McMaster University, for a guest lecture on Tuesday, July 16 from 11 a.m. to noon in 3-001 Edmonton Clinic Health Academy.
The lecture is entitled, "Academic health technology assessment: An endangered species in Canada?" Xie will talk about how academic researchers have been one of the driving forces in developing and advancing health technology assessment (HTA) and promoting its use in the context of health policymaking worldwide. Unfortunately, Canadian academic HTA groups are struggling with a substantial cut in research funding in the past few years.
Feng Xie will share his experience and observation on challenges and opportunities in academic HTA. More importantly, he would like to engage the audience into the discussion: is it possible to keep the academic HTA identity in Canada and how?
This lecture will be available to live stream by following this link:
A light lunch will be provided.
Feng Xie is a Professor of Health Economics in McMaster's Department of Health Research Methods, Evidence and Impact (HEI) and a member of the Centre for Health Economics and Policy Analysis. His research interests include health technology assessment, economic evaluations using models and trial data, patient-reported outcome and preference measures, and health utility measures.
Dr. Xie is deputy editor-in-chief of the BMC Journal: Health and Quality of Life Outcomes and an associate editor of Medical Decision Making. He received a Career Scientist Award from Ontario Ministry of Health and Long Term Care and a Canadian Institutes of Health Research (CIHR) New Investigator Award.
Dr. Xie has been involved in numerous HTA and economic evaluations in assessing new health technologies to support national and provincial reimbursement decision-making. He is also interested in measuring patient-reported outcomes in the context of clinical trials and economic evaluations. He holds a PhD in pharmacoeconomics and outcomes research from the National University of Singapore; an MSc in pharmacy administration from Fudan University and a BSc in pharmacy from Shanghai Medical University.